Actions
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.


Bearish
4
Neutral
6
Bullish
4
Bearish
7
Neutral
18
Bullish
21
Bearish
3
Neutral
12
Bullish
17
Investor Presentation
Q2 FY27
Investor Presentation
Q2 FY27
Investor Presentation
Q1 FY27
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Investor Presentation
Q4 FY25
Solara Active Pharma Sciences Ltd Partly Paidup (SOLARAPP1) is currently trading at 308.70 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Solara Active Pharma Sciences Limited is an India‑based active pharmaceutical ingredient (API) manufacturer and CRAMS/CMO services provider supplying regulated markets with complex chemistries and captive products across multiple therapeutic areas under the Solara platform, operating accredited facilities including Mangalore, Cuddalore and a mothballed Vizag site. Q2 FY27 marked a strong recovery: consolidated revenue of INR418 crores (up 33% YoY), EBITDA more than doubled to INR77 crores, and PAT returned to INR28.5 crores versus a prior‑year loss; base business revenue was INR327 crores and regulated markets comprised about 78% of sales, indicating a favorable product mix. Management highlighted margin recovery drivers: base business gross margins above 50% and ibuprofen margins improving to about 36% this quarter, with overall gross margin at 47.2%; EBITDA margin expansion to 18.4% resulted from stable operating costs and improved gross margin flow through despite raw material and shipping disruptions. Balance sheet and cash focus are evident — net debt reduced from ~INR614 crores to ~INR500 crores in H1, lowering net debt/EBITDA to about 1.8x; management emphasized working capital discipline, monetization of idle assets at Vizag, and a continued focus on funding growth capex while preserving leverage ratios.
Over the past 52 weeks, Solara Active Pharma Sciences Ltd Partly Paidup has traded between a low of ₹270.00 and a high of ₹445.40. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Solara Active Pharma Sciences Ltd Partly Paidup has a market capitalization of approximately 5.56. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Solara Active Pharma Sciences Ltd Partly Paidup’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of N/A and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 5.56 Cr, Solara Active Pharma Sciences Ltd Partly Paidup is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Solara Active Pharma Sciences Ltd Partly Paidup operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Solara Active Pharma Sciences Ltd Partly Paidup is N/A. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Revenue was reported at INR384 crore (total income INR384.29 crore), EBITDA at INR63.5 crore, and PAT at INR16.3 crore for Q1 FY27.
The board met on July 23, 2026 to consider and approve the unaudited standalone and consolidated results for the quarter ended June 30, 2026.
—
—
6 Cr
Moderate Risk
0.0
28.9
—
0.0
445.40
270.00
Sales CAGR
Profit CAGR
ROE
ROCE